JAK2-IN-7

CAT: 0804-HY-131906-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-131906-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities[1].
CAS Number
[2593402-36-7]
UNSPSC
12352005
Target
Apoptosis; FLT3; JAK
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jak2-in-7.html
Purity
99.15
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
CC1=C(N=C(N=C1)NC2=CC=C3CN(CCC3=C2)C(/C=C/CN(C)C)=O)C4=CN(N=C4)C(C)C
Molecular Formula
C26H33N7O
Molecular Weight
459.59
References & Citations
[1]Yang T, et al. N- (Pyrimidin-2-yl) -1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01488.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3; Tyk2

Related Products

CatalogName
HY-146066-01α7 nAchR-JAK2-STAT3 agonist 1
HY-146066A-01(R) -α7 nAchR-JAK2-STAT3 agonist 1
HY-155746JAK2-IN-9
HY-176479JAK2-IN-12
HY-179687JAK2-IN-18
HY-179428JAK2-IN-17
HY-161684-01JAK2-IN-10
HY-178936JAK2-IN-15
HY-175684JAK2-IN-14
HY-174988JAK2-IN-13

Alternative Products

CatalogName
MBS3616634-01JAK2-IN-7
MBS3606718-01JAK2 inhibitor G5-7
MF-0036202-01α7 nAchR-JAK2-STAT3 agonist 1
ant-644JAK2

Popular Products